Highest Price Target1
Lowest Price Target1
Consensus Price Target1
Analyst Rating Summary1
Analyst Firms Making Recommendations1
- JP Morgan
- Goldman Sachs
- Raymond James
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for BridgeBio Pharma
What is the target price for BridgeBio Pharma (BBIO)?
The latest price target for BridgeBio Pharma (NASDAQ: BBIO) was reported by Mizuho on August 28, 2023. The analyst firm set a price target for $60.00 expecting BBIO to rise to within 12 months (a possible 125.73% upside). 15 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for BridgeBio Pharma (BBIO)?
The latest analyst rating for BridgeBio Pharma (NASDAQ: BBIO) was provided by Mizuho, and BridgeBio Pharma reiterated their buy rating.
When is the next analyst rating going to be posted or updated for BridgeBio Pharma (BBIO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BridgeBio Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BridgeBio Pharma was filed on August 28, 2023 so you should expect the next rating to be made available sometime around August 28, 2024.
Is the Analyst Rating BridgeBio Pharma (BBIO) correct?
While ratings are subjective and will change, the latest BridgeBio Pharma (BBIO) rating was a reiterated with a price target of $0.00 to $60.00. The current price BridgeBio Pharma (BBIO) is trading at is $26.58, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.